Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Starrygene (https://www.starrygene.com/) is a clinical stage biotechnology company based in China, focused on XMVA09, a novel AAV-vector expressing anti-VEGF-A+Ang2 bispecific Ab which is in a Phase 1 study as an Intravitreally- injected therapeutic for wet AMD (wAMD) and diabetic macular edema (DME). XMVA09 selectively targets the retinal pigment epithelium.

AAV-drugs are known to be cost-effective with significantly reduced injection frequency of antibody-based drugs.

Starrygene has engaged Cenponts and The Sage Group to secure a license/ partnership to advance XMVA09 in clinical and commercial development.

Currently, AMD affects more than 200 million people worldwide. It is projected that its frequency will increase due to the aging population in many countries. Approximately 20% of AMD patients have the “wet” form.

 DME is a common complication of diabetes, impacting around 4-7% of diabetic patients worldwide.

A Phase 1 trial focused on wAMD was launched in China in June 2024. An IND  for the DME indication has been approved in China.

In an IIT study with six wAMD patients, data showed  safety excellent therapeutic effects. XMVA09 in the clinic is thus demonstrating promising potential in terms of reliable safety, good tolerability, and efficacy in the management of wAMD.

An abundance of preclinical data with XMVA09 has shown safety and efficacy in a variet of mouse and non-human primate models.

Worldwide (PCT) patent and national applications have been filed pertaining to the compound,  its preparation and use.

We welcome the opportunity to organise a Zoom or Teams call to introduce Starrygene and discuss potential collaboration on XMVA09.